Publications by authors named "Rodolfo F Perini"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

36

Total Likes

350

Extended Reach

2,768,266

Social Features

167
P
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.
Brian I Rini, Elizabeth R Plimack, Viktor Stus, Rustem Gafanov, Tom Waddell, Rodolfo F Perini

Nat Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.
Ramaprasad Srinivasan, Othon Iliopoulos, Kathryn E Beckermann, Vivek Narayan, Benjamin L Maughan, Rodolfo F Perini

Lancet Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia.
Hsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, Satoshi Tamada, Nobuaki Matsubara, Rodolfo F Perini

Jpn J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.
Thomas Powles, Toni K Choueiri, Laurence Albiges, Katriina Peltola, Guillermo de Velasco, Rodolfo F Perini

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum.
Henry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, Jay Chhablani, Ane Bundsbæk Bøndergaard Iversen, Rodolfo F Perini

Ophthalmology· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
Toni K Choueiri, Jaime R Merchan, Robert Figlin, David F McDermott, Edward Arrowsmith, Rodolfo F Perini

Lancet Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.
Henry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, Jay Chhablani, Ane Bundsbæk Bøndergaard Iversen, Rodolfo F Perini

Ophthalmology· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling.
Dhananjay D Marathe, Petra M Jauslin, Huub Jan Kleijn, Carolina De Miranda Silva, Anne Chain, Rodolfo F Perini

J Clin Pharmacol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.
Othon Iliopoulos, Ane B Iversen, Vivek Narayan, Benjamin L Maughan, Kathryn E Beckermann, Rodolfo F Perini

Lancet Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma.
Jason J Luke, Georgina V Long, Caroline Robert, Matteo S Carlino, Toni K Choueiri, Rodolfo F Perini

Eur J Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Toni K Choueiri, Thomas Powles, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Rodolfo F Perini

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
Tobias Else, Eric Jonasch, Othon Iliopoulos, Kathryn E Beckermann, Vivek Narayan, Rodolfo F Perini

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Toni K Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Stefan Symeonides, Rodolfo F Perini

Oncologist· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, Elizabeth R Plimack, Jaime R Merchan, Rodolfo F Perini

Eur J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Toni K Choueiri, Thomas Powles, Martin H Voss, Elizabeth R Plimack, Howard Gurney, Rodolfo F Perini

Future Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.
Neil J Shah, Sneha D Sura, Reshma Shinde, Junxin Shi, Puneet Singhal, Rodolfo F Perini

Urol Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
Dhananjay D Marathe, Petra M Jauslin, Huub Jan Kleijn, Carolina de Miranda Silva, Anne Chain, Rodolfo F Perini

CPT Pharmacometrics Syst Pharmacol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
Sun Young Rha, Toni K Choueiri, Vsevolod B Matveev, Anna Alyasova, Sung-Hoo Hong, Rodolfo F Perini

Int J Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Laurence Albiges, Howard Gurney, Vagif Atduev, Cristina Suarez, Miguel A Climent, Rodolfo F Perini

Lancet Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.
Robert Motzer, Saby George, Jaime R Merchan, Thomas E Hutson, Xun Song, Rodolfo F Perini

Oncologist· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Toni K Choueiri, Masatoshi Eto, Robert Motzer, Ugo De Giorgi, Tomas Buchler, Rodolfo F Perini

Lancet Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era.
Neil J Shah, Sneha D Sura, Reshma Shinde, Junxin Shi, Puneet K Singhal, Rodolfo F Perini

Eur Urol Open Sci· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
Jens Bedke, Brian I Rini, Elizabeth R Plimack, Viktor Stus, Rustem Gafanov, Rodolfo F Perini

Eur Urol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Robert Motzer, Camillo Porta, Boris Alekseev, Sun Young Rha, Toni K Choueiri, Rodolfo F Perini

Lancet Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis